Axalbion is a clinical-stage pharmaceutical company developing TRPM8 agonists for the treatment of chronic cough. Axalbion’s s strategy is to develop its lead compound AX-8 up-to Phase 2b to show clinical proof of concept across a representative patient population.
Location
-
PSE C, 1015 Lausanne, Switzerland
Additional address info
- EPFL Innovation Park, Bat C
Canton
Facts & figures
-
Type of organizationPrivate company
-
Year of foundation2017
-
Number of employees in Switzerland1-9
Core competencies
Keep browsing
You may also be interested in
Memorises Bio AG 
- R&D
Member
Pilatus Biosciences SA
- R&D
Member
Step Pharma SAS
- R&D
Member